Categories
Lung Cancer

LEAP-015: lenvatinib + pembrolizumab + mFOLFOX6 in advanced/met gastroesophageal adenocarcinoma [Video]

Kohei Shitara, National Cancer Center Hospital East, Kashiwa, Japan talks about the rationale and trial design of the Phase III LEAP-015 (NCT04662710) trial, randomized clinical study investigating the efficacy and safety of lenvatinib plus pembrolizumab plus mFOLFOX6 in patients with advanced gastroesophageal cancer. The trial consists of two parts; part one is treatment with lenvantinib in combination with pembrolizumab and chemotherapy; part two is randomization to receive lenvatinib plus pembrolizumab plus chemotherapy, or chemotherapy alone. Primary endpoints include overall-survival (OS) and progression-free survival (PFS). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Categories
Lung Cancer

Immunotherapies in Lung Cancer | 2022 Evolution Conference [Video]

The availability of immunotherapies, such as checkpoint inhibitor drugs, has been transformative across many different cancer types. In this session, Dr Ibiayi Dagogo-Jack from Mass General Cancer Center discusses how these therapies are helping to reshape treatment paradigms in the lung cancer setting.To obtain credit for this CME activity you must watch the full 2022 Evolution Conference Playlist. Information on obtaining CME/CE Credits and MOC points can be found in the playlist description.